Loading...
MCOV B logo
MCOV B
Medicover

Rising European Labor Costs And Regulatory Burdens Will Squeeze Margins

Published
03 Aug 25
Updated
12 Dec 25
Views
6
n/a
n/a
AnalystLowTarget's Fair Value
n/a
Loading
1Y
14.2%
7D
0.5%

Author's Valuation

SEK 230.734.9% undervalued intrinsic discount

AnalystLowTarget Fair Value

Narrative
Updates1

Shared on 12 Dec 25

Fair value Increased 5.33%

MCOV B Expects MRD Assay Validation To Support Balanced Long Term Outlook

Analysts have raised their price target on Medicover from €219.05 to €230.73, citing slightly stronger expectations for revenue growth and profit margins that more than offset a modestly higher discount rate and a marginally lower assumed future P/E multiple. What's in the News Additional DART clinical study results from Oslo University Hospital further validate Medicover Genetics' ctDNA-based MRD assay as a strong predictor of disease progression in unresectable stage III NSCLC, supporting its path toward clinical validation and commercialisation (Key Developments) The updated DART data set, now including 640 plasma samples from 84 patients, shows that detectable ctDNA during and after durvalumab treatment following chemoradiotherapy is strongly associated with inferior progression free survival, underscoring the assay's prognostic value (Key Developments) Detection of ctDNA at six months after initiation of durvalumab and three months after its completion is linked to significantly poorer progression free survival, with ctDNA often indicating disease progression a median of 7.4 months before imaging.
Read more